Martiskainen, Henna

Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway

Gabbouj, S., Ryhänen, S., Marttinen, M., Wittrahm, R., Takalo, M., Kemppainen, S., Martiskainen, H., Tanila, H., Haapasalo, A., Hiltunen, M., et al. (2019) · Frontiers in Neuroscience

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 401

The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions

Takalo, M., Wittrahm, R., Wefers, B., Parhizkar, S., Jokivarsi, K., Kuulasmaa, T., Mäkinen, P., Martiskainen, H., Wurst, W., Xiang, X., et al. (2020) · Molecular Neurodegeneration

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 83

Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models

Martiskainen, H., Viswanathan, J., Nykänen, N.-P., Kurki, M., Helisalmi, S., Natunen, T., Sarajärvi, T., Kurkinen, K. M. A., Pursiheimo, J.-P., Rauramaa, T., et al. (2015) · Neurobiology of Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 70

Decreased plasma β‐amyloid in the Alzheimer's disease APP A 673 Tvariant carriers

Martiskainen, H., Herukka, S., Stančáková, A., Paananen, J., Soininen, H., Kuusisto, J., Laakso, M., & Hiltunen, M. (2017) · Annals of Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 64

The protective PLCγ2-P522R variant mitigates Alzheimer’s disease-associated pathologies by enhancing beneficial microglial functions

Takalo, M., Jeskanen, H., Rolova, T., Kervinen, I., Hellén, M., Heikkinen, S., Koivisto, H., Jokivarsi, K., Müller, S. A., Koivumäki, E.-M., et al. (2025) · Journal of Neuroinflammation

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 15

Protective PLCG2 variants associate with a delayed onset of Alzheimer’s disease among heterozygous APOE ε4 carriers

Jeskanen, H., Heikkinen, S., Kervinen, I., Lehtisalo, J., Ngandu, T., Willman, R.-M., Rosa, J., Hoffmann, D., FinnGen, Leinonen, V., et al. (2026) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 1

PLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures

Coulon, A., Rabiller, F., Takalo, M., Roy, A., Pelletier, A., Martiskainen, H., Siedlecki-Wullich, D., Lannette-Weimann, N., Majerníková, N., Grenon, A., et al. (2026) · Nature Genetics

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 1

Genetic Validation of ABI3 p.S209F Variant and Its effects On Early Brain Pathology in Asymptomatic Elderly Individuals

Koivumäki, M., Martiskainen, H., Takalo, M., Lehtisalo, J., Ngandu, T., Snellman, A., Hiltunen, M., & Rinne, J. O. (2025) · Research Square

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 0